Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Jun 7.

Published in final edited form as: Hematol Oncol Clin North Am. 2009 Oct;23(5):949–v. doi: 10.1016/j.hoc.2009.07.005

Outcome for precursor B-cell ALL treated with hyper-CVAD in the pre-rituximab era by age category and CD20 status (positive or negative) using the 10% demarcation of expression. The 3-year rates for CRD (A) and OS (B) were nearly identical to those observed with the traditional cut point of 20% for CD20 expression.¹⁰

Outcome for precursor B-cell ALL treated with hyper-CVAD in the pre-rituximab era by age category and CD20 status (positive or negative) using the 10% demarcation of expression. The 3-year rates for CRD (A) and OS (B) were nearly identical to those observed with the traditional cut point of 20% for CD20 expression.¹⁰